412 related articles for article (PubMed ID: 26176182)
21. A stimulatory thyrotropin receptor antibody (M22) and thyrotropin increase interleukin-6 expression and secretion in Graves' orbital preadipocyte fibroblasts.
Kumar S; Schiefer R; Coenen MJ; Bahn RS
Thyroid; 2010 Jan; 20(1):59-65. PubMed ID: 20017620
[TBL] [Abstract][Full Text] [Related]
22. Pathogenesis of ophthalmopathy in autoimmune thyroid disease.
Heufelder AE
Rev Endocr Metab Disord; 2000 Jan; 1(1-2):87-95. PubMed ID: 11704996
[TBL] [Abstract][Full Text] [Related]
23. Thyrotropin receptor-stimulating Graves' disease immunoglobulins induce hyaluronan synthesis by differentiated orbital fibroblasts from patients with Graves' ophthalmopathy not only via cyclic adenosine monophosphate signaling pathways.
van Zeijl CJ; Fliers E; van Koppen CJ; Surovtseva OV; de Gooyer ME; Mourits MP; Wiersinga WM; Miltenburg AM; Boelen A
Thyroid; 2011 Feb; 21(2):169-76. PubMed ID: 20954819
[TBL] [Abstract][Full Text] [Related]
24. A stimulatory TSH receptor antibody enhances adipogenesis via phosphoinositide 3-kinase activation in orbital preadipocytes from patients with Graves' ophthalmopathy.
Kumar S; Nadeem S; Stan MN; Coenen M; Bahn RS
J Mol Endocrinol; 2011 Jun; 46(3):155-63. PubMed ID: 21321093
[TBL] [Abstract][Full Text] [Related]
25. TSH receptor transcripts and TSH receptor-like immunoreactivity in orbital and pretibial fibroblasts of patients with Graves' ophthalmopathy and pretibial myxedema.
Stadlmayr W; Spitzweg C; Bichlmair AM; Heufelder AE
Thyroid; 1997 Feb; 7(1):3-12. PubMed ID: 9086563
[TBL] [Abstract][Full Text] [Related]
26. Current insights into the pathogenesis of Graves' orbitopathy.
Eckstein AK; Johnson KT; Thanos M; Esser J; Ludgate M
Horm Metab Res; 2009 Jun; 41(6):456-64. PubMed ID: 19530272
[TBL] [Abstract][Full Text] [Related]
27. Chitosan inhibits inflammation and adipogenesis of orbital fibroblasts in Graves ophthalmopathy.
Xiong H; Wu M; Zou H; Jiang S; Yi H; Yi T; Wang Q; Liu D; Zhou Y; Wei C; Zhou X
Mol Vis; 2018; 24():509-517. PubMed ID: 30090014
[TBL] [Abstract][Full Text] [Related]
28. Modulation of expression of somatostatin receptor subtypes in Graves' ophthalmopathy orbits: relevance to novel analogs.
Cozma I; Zhang L; Uddin J; Lane C; Rees A; Ludgate M
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1630-5. PubMed ID: 17848636
[TBL] [Abstract][Full Text] [Related]
29. Modeling Graves' Orbitopathy in Experimental Graves' Disease.
Banga JP; Moshkelgosha S; Berchner-Pfannschmidt U; Eckstein A
Horm Metab Res; 2015 Sep; 47(10):797-803. PubMed ID: 26287396
[TBL] [Abstract][Full Text] [Related]
30. Role of Proprotein Convertase Subtilisin/Kexin Type 9 in the Pathogenesis of Graves' Orbitopathy in Orbital Fibroblasts.
Lee GE; Kim J; Lee JS; Ko J; Lee EJ; Yoon JS
Front Endocrinol (Lausanne); 2020; 11():607144. PubMed ID: 33488522
[TBL] [Abstract][Full Text] [Related]
31. Anti-oxidative and anti-adipogenic effects of caffeine in an in vitro model of Graves' orbitopathy.
Ko J; Kim JY; Kim JW; Yoon JS
Endocr J; 2020 Apr; 67(4):439-447. PubMed ID: 31941844
[TBL] [Abstract][Full Text] [Related]
32. miR-199a Downregulation as a Driver of the NOX4/HIF-1α/VEGF-A Pathway in Thyroid and Orbital Adipose Tissues from Graves' Patients.
Craps J; Joris V; Baldeschi L; Daumerie C; Camboni A; Buemi A; Lengelé B; Behets C; Boschi A; Mourad M; Many MC; Dessy C
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008579
[TBL] [Abstract][Full Text] [Related]
33. A Promising Mouse Model of Graves' Orbitopathy Induced by Adenovirus Expressing Thyrotropin Receptor A Subunit.
Zhang M; Ding X; Wu LP; He MQ; Chen ZY; Shi BY; Wang Y
Thyroid; 2021 Apr; 31(4):638-648. PubMed ID: 33076782
[No Abstract] [Full Text] [Related]
34. PERK mediates oxidative stress and adipogenesis in Graves' orbitopathy pathogenesis.
Ko J; Kim JY; Kyoung Chae M; Jig Lee E; Sook Yoon J
J Mol Endocrinol; 2021 May; 66(4):313-323. PubMed ID: 33870911
[TBL] [Abstract][Full Text] [Related]
35. Inhibitory Effect of Idelalisib, a Selective Phosphatidylinositol 3-Kinase δ Inhibitor, on Adipogenesis in an In Vitro Model of Graves' Orbitopathy.
Ko J; Kim JY; Lee EJ; Yoon JS
Invest Ophthalmol Vis Sci; 2018 Sep; 59(11):4477-4485. PubMed ID: 30193323
[TBL] [Abstract][Full Text] [Related]
36. Thalidomide inhibits adipogenesis of orbital fibroblasts in Graves' ophthalmopathy.
Zhang C; Zhang X; Ma L; Peng F; Huang J; Han H
Endocrine; 2012 Apr; 41(2):248-55. PubMed ID: 22237514
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms in Graves Eye Disease: Apoptosis as the End Point of Insulin-Like Growth Factor 1 Receptor Inhibition.
Morshed SA; Ma R; Latif R; Davies TF
Thyroid; 2022 Apr; 32(4):429-439. PubMed ID: 34927457
[No Abstract] [Full Text] [Related]
38. Demonstration of thyrotropin receptor mRNA in orbital fat and eye muscle tissues from patients with Graves' ophthalmopathy by in situ hybridization.
Wu SL; Yang CS; Wang HJ; Liao CL; Chang TJ; Chang TC
J Endocrinol Invest; 1999 Apr; 22(4):289-95. PubMed ID: 10342363
[TBL] [Abstract][Full Text] [Related]
39. Antioxidant Actions of Selenium in Orbital Fibroblasts: A Basis for the Effects of Selenium in Graves' Orbitopathy.
Rotondo Dottore G; Leo M; Casini G; Latrofa F; Cestari L; Sellari-Franceschini S; Nardi M; Vitti P; Marcocci C; Marinò M
Thyroid; 2017 Feb; 27(2):271-278. PubMed ID: 27824294
[TBL] [Abstract][Full Text] [Related]
40. Biological effects of thyrotropin receptor activation on human orbital preadipocytes.
Zhang L; Baker G; Janus D; Paddon CA; Fuhrer D; Ludgate M
Invest Ophthalmol Vis Sci; 2006 Dec; 47(12):5197-203. PubMed ID: 17122103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
